California Judge Advises Biogen and Genentech to Limit Monetary Discussions in Patent Royalty Trial

In an important development concerning the ongoing legal dispute between Biogen and Genentech, a California federal judge has advised both parties to refrain from discussing the “magnitude of the money at issue” during their breach of contract trial. The case centers around alleged patent royalties owed due to sales of Biogen’s multiple sclerosis medication. The judge’s guidance appears to be driven by the composition of the jury, which is thought to predominantly consist of individuals “not of significant means.” For a more detailed examination of the case, please refer to the original article published by Law360.